SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese owner and operator of aesthetic medical clinics, has officially entered the U.S. market through the completion of a strategic investment in OrangeTwist, a U.S.-based medspa chain. This investment represents the initial phase of SBC's "full-scale" strategic expansion in the United States, leveraging its existing global network of 258 affiliated clinics and over six million annual patient visits.
OrangeTwist specializes in non-invasive aesthetic treatments, operating 24 locations across six U.S. states and offering injectable, energy-based, and regenerative treatments. According to SBC, OrangeTwist's advanced management system—which integrates procurement, clinical workflows, and real-time KPI tracking—provides operational consistency that supports scalable growth. The partnership will enable joint operations, with both companies planning to sell each other's services and products in the U.S. and Japan while collaborating on new beauty products and services.
"OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine," said Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings. "We look forward to combining their strengths with our expertise and global network to accelerate growth across Asia and beyond." Robert Settembro, CEO of OrangeTwist, added that the partnership allows the company to "bring exceptional aesthetic experiences to more communities while leveraging SBC's global expertise."
The U.S. medical aesthetics industry represents a significant growth opportunity, with SBC reporting forecasts of expansion from $34 billion today to $48 billion by 2030. Drivers of demand include injectables, fillers, laser treatments, and body contouring procedures that offer minimal risk and downtime, alongside an aging population seeking aesthetic treatments. This market potential makes the U.S. a critical component of SBC's international growth strategy.
This investment in OrangeTwist constitutes Phase One of SBC's multiyear roadmap to establish a leading position in medical aesthetics and wellness markets internationally, with particular focus on the U.S. and Southeast Asia. During 2026, SBC plans additional strategic investments and partnerships similar to its recent e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand. As part of that agreement, SBC will provide management support for a new dermatology clinic BLEZ is preparing to open in Bangkok.
Phase Two of SBC's expansion plan, scheduled for 2027-2028, will focus on select acquisitions and joint ventures to accelerate growth and enhance competitive positioning. Phase Three, commencing in 2029 and beyond, anticipates SBC achieving leadership positions in the U.S., Southeast Asia, and other key markets. The OrangeTwist investment provides SBC with an immediate operational foothold in the lucrative U.S. market while establishing a template for future international partnerships.
